ReviewHepatic medicine : evidence and research2026
Research Trends and Hotspots in Mendelian Randomization Studies of Liver Diseases: A Bibliometric and Visualization Analysis.
Review in Hepatic medicine : evidence and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study conducted a bibliometric analysis of Mendelian randomization (MR) research in liver diseases from 2014 to 2025 using the Web of Science Core Collection (WoSCC) and PubMed databases. A total of 304 WoSCC records and 10 clinical studies were included. Publications showed a steady upward trend, with China contributing the most (n=251), followed by the United States and United Kingdom. Zhejiang University led institutional output (n=18), and Chen Lanlan was the most prolific author (n=8). Frontiers in Endocrinology was the most productive journal (n=21). Current hotspots include gut microbiota, metabolism, and insulin resistance. Clinical studies focused on metabolic dysfunction-associated steatotic liver disease (MASLD), covering risk factors, comorbidities, and clinical outcomes. This is the first comprehensive bibliometric study in this field, providing a reliable reference for future research directions. However, the generalizability of our findings is constrained by the coverage scope of the databases and the language of the included literature, which may introduce selection bias. In addition, the causal inferences drawn from the included MR studies are subject to the validity of instrumental variables and the generalizability across populations, which may limit the applicability of our conclusions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.